CommercialCoverageLow impact
06.02.17h, Serodiagnosis of Inflammatory Bowel Disease (IBD) and the Prometheus® IBD sgi Diagnostic™ Test
Independence Blue Cross·Gastroenterology, Pathology, Internal Medicine·Pharmacy
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued policy 06.02.17h confirming that serodiagnosis of inflammatory bowel disease (IBD) and Prometheus® IBD sgi Diagnostic™ testing remain experimental/investigational and are NOT covered. This is a reaffirmation of existing non-coverage with no substantive changes to billing or coverage policy.
Action Required
No immediate billing action required. This is a policy reaffirmation only. Billing team should verify that claims for CPT codes 0164U, 83516, 83520, and 88350 when billed for IBD serodiagnosis continue to be denied as experimental/investigational. Ensure that any standing orders or clinical decision support systems reject Prometheus IBD testing requests for Independence Blue Cross commercial members. No workflow changes are necessary unless your practice previously submitted these claims as covered services.